Wockhardt has recalled 1,62,142 cartons of various drugs, which are used to treat ailments like high blood pressure and ulcer, from the US market due to deviations in current good manufacturing practice norms laid down by the American health regulator. As per the US Food and Drug Administration (USFDA), Mumbai-based company has recalled the drugs for current good manufacturing practice (CGMP) deviations.
Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.
